What is the IDYA stock price?

IDEAYA Biosciences, Inc. (IDYA) last available close: $31.33, as of 11/3/26. Prices on Cylvex may be delayed.

How many analyst price targets for IDYA were reached?

9 of 22 published price targets for IDYA were reached within 12 months (41% reached); 12 are still open. Counts only — firm names and target values are shown to signed-in members.

How many firms publish price targets or ratings on IDYA?

16 firms have published price targets or ratings on IDYA that Cylvex tracks. Counts only — firm names and target values are shown to signed-in members.

Is this investment advice?

No. Cylvex is an educational and informational platform; nothing on this page is investment, financial or trading advice. Past analyst targets do not predict future results.

NASDAQ

Updated Nov 3, 7:59 PM ET

IDYA

IDEAYA Biosciences, Inc.

$31.27CS band Mixed

−$0.31 (0.98%) At close $31.33 · Today

☾After Hours −$0.06 (0.21%) Nov 3, 7:59 PM ET

About IDYA

IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.

Cylvex Score

Mixed

Some risk factors elevated

Multi-factor score. Not a buy/sell signal.

Score history

Calibrating

Score history is calibrating — it appears once enough daily scores are recorded.

What goes into the score

6 axes · equal weight

AnalystWall Street consensus & target distance

GrowthEarnings growth trajectory

ProfitabilityROE, margins, cash generation

ValuationPE, PEG, price-to-book ratios

TechnicalsPrice momentum & 52-week position

RiskBeta, volatility, leverage

The Cylvex Score is a multi-factor summary for education. Not a buy/sell signal. Not investment advice.